Strand Life Sciences Launches Portal to Help Doctors with Rare Disease Diagnosis; Offers Discounted Testing for Low-Income Patients
Strand Life Sciences launches the StrandOmics Portal, improving rare disease diagnosis with advanced genetic insights.
Breaking News
Mar 01, 2025
Simantini Singh Deo

Bengaluru, February 28, 2025: On the occasion of Rare Disease Day, Strand Life Sciences, a Reliance Industries subsidiary and leading genomics company today launched the StrandOmics Portal to
improve diagnosis of rare diseases.
This new online portal gives clinicians quick and easy access to information on genetic variants, giving them a comprehensive view for each case. This means faster and more accurate diagnosis for patients. In
addition to the portal, Strand Life Sciences will offer rare
disease genetic testing at a reduced cost for patients from economically disadvantaged backgrounds, making these crucial tests more accessible.
The StrandOmics Portal helps doctors by:
Providing clear and quick genetic insights for better diagnosis
Allowing doctors to independently review a broader set of genetic variants
Improving prenatal diagnosis through better collaboration between specialists
Dr Ramesh Hariharan, CEO & Co-Founder of Strand Life Sciences, said, “We are dedicated to improving genetic diagnostics and making it available to everyone. We will continue to innovate and
invest in tools like the StrandOmics Portal to empower
doctors in their fight against rare diseases.”
About Strand Life Sciences
Strand Life Sciences, a subsidiary of Reliance Industries Limited, is a genomics-based research and diagnostics company that combines a long track record in bioinformatics with cutting-edge laboratory
assays and a vast hospital partner network to drive newer
generations of patient care. Strand’s customers include global medical instruments, diagnostic, and pharmaceutical companies.Strand is also a pioneer of genomic testing in India, and its long global
bioinformatics track record makes it the most trusted company
for genomic diagnostics in the areas of oncology, rare diseases, women’s health, and infectious diseases.
Additionally, Strand is actively expanding into consumer genomics, empowering individuals with personalized insights into their genetic makeup. For more information, visit https://strandls.com